One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Zoliflodacin shows benefit as an oral treatment for uncomplicated gonorrhoea
A step forward in the treatment of relapsed or refractory follicular lymphoma
Is proton therapy a new standard of care for oropharyngeal cancer?
Climate change, migration, displacement, and health: past, present, and future
Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma
Revisiting platelet-rich plasma for knee osteoarthritis – Authors' reply
Rethinking CLDN18.2 expression in gastric cancer therapy – Authors' reply
DISTRICTS trial: enhancing carpal tunnel syndrome treatment – Authors' reply
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Lancet Countdown on health and climate change in Africa: an international collaboration for locally led research and action
